Review



jnki  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    MedChemExpress jnki
    Jnki, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 645 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jnki/product/MedChemExpress
    Average 98 stars, based on 645 article reviews
    jnki - by Bioz Stars, 2026-02
    98/100 stars

    Images



    Similar Products

    98
    MedChemExpress jnki
    Jnki, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jnki/product/MedChemExpress
    Average 98 stars, based on 1 article reviews
    jnki - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    94
    MedChemExpress cell permeant peptide d jnki 1
    Cell Permeant Peptide D Jnki 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell permeant peptide d jnki 1/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    cell permeant peptide d jnki 1 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress d jnk1
    D Jnk1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d jnk1/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    d jnk1 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress d jnk 1
    D Jnk 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d jnk 1/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    d jnk 1 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress jnk inhibitor d jnki 1
    Jnk Inhibitor D Jnki 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jnk inhibitor d jnki 1/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    jnk inhibitor d jnki 1 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    98
    MedChemExpress s2735 sp600125 jnki medchemexpress
    S2735 Sp600125 Jnki Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s2735 sp600125 jnki medchemexpress/product/MedChemExpress
    Average 98 stars, based on 1 article reviews
    s2735 sp600125 jnki medchemexpress - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    94
    Selleck Chemicals jnk inhibitor jnki
    Fig. 4 Knockdown of ITGB3 promotes osteogenic differentiation in osteosarcoma by activating the <t>JNK/c-JUN/RUNX2</t> pathway. ITGB3-knockdown (IT GB3-KD) and ITGB3-negative control (ITGB3-NC) HOS and U2OS cells were subjected to either 8 Gy of irradiation (IR) or non-IR treatment, and additional groups were established via the application of a JNK inhibitor (SP600125, <t>JNKi)</t> 4 h before the IR or non-IR treatment to perform rescue experiments. Protein samples were collected 24 h posttreatment for western blot analysis to explore the regulatory effect of ITGB3-KD on the JNK/c-JUN pathway (A, C, and E) and whether the JNK/c-JUN pathway directly regulated osteogenic differentiation (B, D, and F) in HOS and U2OS cells. *P<0.05, **P<0.01, ***P<0.001, ns = not significant
    Jnk Inhibitor Jnki, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jnk inhibitor jnki/product/Selleck Chemicals
    Average 94 stars, based on 1 article reviews
    jnk inhibitor jnki - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    97
    MedChemExpress jnk inhibitor tanzisertib jnki
    Fig. 4 Knockdown of ITGB3 promotes osteogenic differentiation in osteosarcoma by activating the <t>JNK/c-JUN/RUNX2</t> pathway. ITGB3-knockdown (IT GB3-KD) and ITGB3-negative control (ITGB3-NC) HOS and U2OS cells were subjected to either 8 Gy of irradiation (IR) or non-IR treatment, and additional groups were established via the application of a JNK inhibitor (SP600125, <t>JNKi)</t> 4 h before the IR or non-IR treatment to perform rescue experiments. Protein samples were collected 24 h posttreatment for western blot analysis to explore the regulatory effect of ITGB3-KD on the JNK/c-JUN pathway (A, C, and E) and whether the JNK/c-JUN pathway directly regulated osteogenic differentiation (B, D, and F) in HOS and U2OS cells. *P<0.05, **P<0.01, ***P<0.001, ns = not significant
    Jnk Inhibitor Tanzisertib Jnki, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jnk inhibitor tanzisertib jnki/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    jnk inhibitor tanzisertib jnki - by Bioz Stars, 2026-02
    97/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 4 Knockdown of ITGB3 promotes osteogenic differentiation in osteosarcoma by activating the JNK/c-JUN/RUNX2 pathway. ITGB3-knockdown (IT GB3-KD) and ITGB3-negative control (ITGB3-NC) HOS and U2OS cells were subjected to either 8 Gy of irradiation (IR) or non-IR treatment, and additional groups were established via the application of a JNK inhibitor (SP600125, JNKi) 4 h before the IR or non-IR treatment to perform rescue experiments. Protein samples were collected 24 h posttreatment for western blot analysis to explore the regulatory effect of ITGB3-KD on the JNK/c-JUN pathway (A, C, and E) and whether the JNK/c-JUN pathway directly regulated osteogenic differentiation (B, D, and F) in HOS and U2OS cells. *P<0.05, **P<0.01, ***P<0.001, ns = not significant

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Enhancing radiosensitivity of osteosarcoma by ITGB3 knockdown: a mechanism linked to enhanced osteogenic differentiation status through JNK/c-JUN/RUNX2 pathway activation.

    doi: 10.1186/s13046-025-03417-4

    Figure Lengend Snippet: Fig. 4 Knockdown of ITGB3 promotes osteogenic differentiation in osteosarcoma by activating the JNK/c-JUN/RUNX2 pathway. ITGB3-knockdown (IT GB3-KD) and ITGB3-negative control (ITGB3-NC) HOS and U2OS cells were subjected to either 8 Gy of irradiation (IR) or non-IR treatment, and additional groups were established via the application of a JNK inhibitor (SP600125, JNKi) 4 h before the IR or non-IR treatment to perform rescue experiments. Protein samples were collected 24 h posttreatment for western blot analysis to explore the regulatory effect of ITGB3-KD on the JNK/c-JUN pathway (A, C, and E) and whether the JNK/c-JUN pathway directly regulated osteogenic differentiation (B, D, and F) in HOS and U2OS cells. *P<0.05, **P<0.01, ***P<0.001, ns = not significant

    Article Snippet: In the cell experiments, cells treated with the JNK inhibitor (JNKi) received SP600125 (Selleck, S1460) at a final concentration of 10 μM, which was introduced into the culture medium 4 h before the application of either irradiation (IR) or non-IR treatments.

    Techniques: Knockdown, Negative Control, Irradiation, Western Blot

    Fig. 5 Knockdown of ITGB3 radiosensitizes osteosarcoma cells by promoting apoptosis through activating the JNK/c-JUN pathway. ITGB3-knockdown (ITGB3-KD) and ITGB3-negative control (ITGB3-NC) HOS and U2OS cells were subjected to either 8 Gy of irradiation (IR) or non-IR treatment, and additional groups were established in which a JNK inhibitor (SP600125, JNKi) was applied 4 h before the IR or non-IR treatment to perform rescue experiments. The apoptosis rates in HOS (A) and U2OS (B) cells were determined 24 h posttreatment using flow cytometry (n = 3 per group). Protein samples were col lected 24 h posttreatment for western blot analysis to explore the regulatory effect of the JNK/c-JUN pathway on apoptosis (C, D) in HOS and U2OS cells. *P<0.05, **P<0.01, ***P<0.001, ns = not significant

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Enhancing radiosensitivity of osteosarcoma by ITGB3 knockdown: a mechanism linked to enhanced osteogenic differentiation status through JNK/c-JUN/RUNX2 pathway activation.

    doi: 10.1186/s13046-025-03417-4

    Figure Lengend Snippet: Fig. 5 Knockdown of ITGB3 radiosensitizes osteosarcoma cells by promoting apoptosis through activating the JNK/c-JUN pathway. ITGB3-knockdown (ITGB3-KD) and ITGB3-negative control (ITGB3-NC) HOS and U2OS cells were subjected to either 8 Gy of irradiation (IR) or non-IR treatment, and additional groups were established in which a JNK inhibitor (SP600125, JNKi) was applied 4 h before the IR or non-IR treatment to perform rescue experiments. The apoptosis rates in HOS (A) and U2OS (B) cells were determined 24 h posttreatment using flow cytometry (n = 3 per group). Protein samples were col lected 24 h posttreatment for western blot analysis to explore the regulatory effect of the JNK/c-JUN pathway on apoptosis (C, D) in HOS and U2OS cells. *P<0.05, **P<0.01, ***P<0.001, ns = not significant

    Article Snippet: In the cell experiments, cells treated with the JNK inhibitor (JNKi) received SP600125 (Selleck, S1460) at a final concentration of 10 μM, which was introduced into the culture medium 4 h before the application of either irradiation (IR) or non-IR treatments.

    Techniques: Knockdown, Negative Control, Irradiation, Flow Cytometry, Western Blot

    Fig. 7 Knockdown of ITGB3 exerts a radiosensitizing effect in osteosarcoma mouse models. ITGB3-knockdown (ITGB3-KD) and ITGB3-negative control (ITGB3-NC) HOS cells were injected into the inguinal subcutaneous region of BALB/c nude mice to establish a subcutaneous tumor model. Additionally, groups of mice receiving intraperitoneal injections of the JNK inhibitor (SP600125, JNKi) were established, with injections administered 24 h before, 4 h before, and daily after 20 Gy of local irradiation (IR) or non-IR treatment. Six days after receiving IR or non-IR treatment, mice were euthanized. Subsequent ly, the subcutaneous tumors were photographed (A), and the growth curves of the tumors were plotted, with n = 6 per group (B). ITGB3 immunohisto chemical staining was performed on subcutaneous tumor specimens from each group, and images were captured at 200x magnification (C). Statistical analysis of ITGB3 expression levels was conducted using the integrated optical density (IOD) method, with n = 3 per group. Furthermore, ITGB3-KD and ITGB3-NC HOS cells were injected into the tibial bone marrow cavity to establish an orthotopic tibial tumor model in BALB/c nude mice. The first biolumi nescence measurement was conducted before 20 Gy of local IR or non-IR treatment. On the 6th day after treatment, bioluminescence measurement was repeated to calculate the ratio of bioluminescent flux increase in the tumor area of each mouse, reflecting tumor growth. Typical images are presented (D). Note: The bioluminescent flux scale has been standardized. *P<0.05, **P<0.01, ***P<0.001, ns = not significant

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Enhancing radiosensitivity of osteosarcoma by ITGB3 knockdown: a mechanism linked to enhanced osteogenic differentiation status through JNK/c-JUN/RUNX2 pathway activation.

    doi: 10.1186/s13046-025-03417-4

    Figure Lengend Snippet: Fig. 7 Knockdown of ITGB3 exerts a radiosensitizing effect in osteosarcoma mouse models. ITGB3-knockdown (ITGB3-KD) and ITGB3-negative control (ITGB3-NC) HOS cells were injected into the inguinal subcutaneous region of BALB/c nude mice to establish a subcutaneous tumor model. Additionally, groups of mice receiving intraperitoneal injections of the JNK inhibitor (SP600125, JNKi) were established, with injections administered 24 h before, 4 h before, and daily after 20 Gy of local irradiation (IR) or non-IR treatment. Six days after receiving IR or non-IR treatment, mice were euthanized. Subsequent ly, the subcutaneous tumors were photographed (A), and the growth curves of the tumors were plotted, with n = 6 per group (B). ITGB3 immunohisto chemical staining was performed on subcutaneous tumor specimens from each group, and images were captured at 200x magnification (C). Statistical analysis of ITGB3 expression levels was conducted using the integrated optical density (IOD) method, with n = 3 per group. Furthermore, ITGB3-KD and ITGB3-NC HOS cells were injected into the tibial bone marrow cavity to establish an orthotopic tibial tumor model in BALB/c nude mice. The first biolumi nescence measurement was conducted before 20 Gy of local IR or non-IR treatment. On the 6th day after treatment, bioluminescence measurement was repeated to calculate the ratio of bioluminescent flux increase in the tumor area of each mouse, reflecting tumor growth. Typical images are presented (D). Note: The bioluminescent flux scale has been standardized. *P<0.05, **P<0.01, ***P<0.001, ns = not significant

    Article Snippet: In the cell experiments, cells treated with the JNK inhibitor (JNKi) received SP600125 (Selleck, S1460) at a final concentration of 10 μM, which was introduced into the culture medium 4 h before the application of either irradiation (IR) or non-IR treatments.

    Techniques: Knockdown, Negative Control, Injection, Irradiation, Staining, Expressing